此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

2019年9月13日 更新者:King's College London

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

研究概览

详细说明

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

研究类型

介入性

注册 (实际的)

42

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • England
      • London、England、英国、SE1 9NH
        • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

35年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
有源比较器:Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Revised QUICKI (RQUICKI)
大体时间:Baseline
Marker of insulin sensitivity
Baseline
RQUICKI
大体时间:day 29
Marker of insulin sensitivity
day 29
RQUICKI
大体时间:day 31
Marker of insulin sensitivity
day 31

次要结果测量

结果测量
措施说明
大体时间
体重
大体时间:基线
基线
腰围
大体时间:基线
基线
臀围
大体时间:基线
基线
血浆葡萄糖浓度
大体时间:基线
禁食
基线
血浆脂联素浓度
大体时间:基线
禁食
基线
血浆瘦素浓度
大体时间:基线
禁食
基线
血浆总胆固醇浓度
大体时间:基线
禁食
基线
血浆低密度脂蛋白 (LDL) 胆固醇浓度
大体时间:基线
禁食
基线
血浆高密度脂蛋白 (HDL) 胆固醇浓度
大体时间:基线
禁食
基线
血浆甘油三酯浓度
大体时间:基线
禁食
基线
血浆总胆固醇:高密度脂蛋白胆固醇比率
大体时间:基线
禁食
基线
体重指数 (BMI)
大体时间:基线
基线
Plasma glucose concentration
大体时间:day 29
Fasting
day 29
Plasma glucose concentration
大体时间:day 31
Fasting
day 31
Plasma insulin concentration
大体时间:Baseline
Fasting
Baseline
Plasma insulin concentration
大体时间:day 29
Fasting
day 29
Plasma insulin concentration
大体时间:day 31
Fasting
day 31
Plasma non-esterified fatty acid concentration
大体时间:Baseline
Fasting
Baseline
Plasma non-esterified fatty acid concentration
大体时间:day 29
Fasting
day 29
Plasma non-esterified fatty acid concentration
大体时间:day 31
Fasting
day 31
Plasma total cholesterol concentration
大体时间:day 29
Fasting
day 29
Plasma total cholesterol concentration
大体时间:day 31
Fasting
day 31
Plasma LDL cholesterol concentration
大体时间:day 29
Fasting
day 29
Plasma LDL cholesterol concentration
大体时间:day 31
Fasting
day 31
Plasma HDL cholesterol concentration
大体时间:day 29
Fasting
day 29
Plasma HDL cholesterol concentration
大体时间:day 31
Fasting
day 31
Plasma triglyceride concentration
大体时间:day 29
Fasting
day 29
Plasma triglyceride concentration
大体时间:day 31
Fasting
day 31
Plasma total cholesterol:HDL cholesterol ratio
大体时间:day 29
Fasting
day 29
Plasma total cholesterol:HDL cholesterol ratio
大体时间:day 31
Fasting
day 31
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
大体时间:Baseline
Fasting (calculated from insulin and glucose)
Baseline
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
大体时间:day 29
Fasting (calculated from insulin and glucose)
day 29
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
大体时间:day 31
Fasting (calculated from insulin and glucose)
day 31
Plasma adiponectin concentration
大体时间:day 29
Fasting
day 29
Plasma adiponectin concentration
大体时间:day 31
Fasting
day 31
Plasma leptin concentration
大体时间:day 29
Fasting
day 29
Plasma leptin concentration
大体时间:day 31
Fasting
day 31
Plasma interleukin-6 concentration
大体时间:Baseline
Fasting
Baseline
Plasma interleukin-6 concentration
大体时间:day 29
Fasting
day 29
Plasma interleukin-6 concentration
大体时间:day 31
Fasting
day 31
Plasma beta-hydroxybutyrate concentration
大体时间:Baseline
Fasting
Baseline
Plasma beta-hydroxybutyrate concentration
大体时间:day 29
Fasting
day 29
Plasma beta-hydroxybutyrate concentration
大体时间:day 31
Fasting
day 31
Plasma norepinephrine concentration
大体时间:Baseline
Fasting
Baseline
Plasma norepinephrine concentration
大体时间:day 29
Fasting
day 29
Plasma norepinephrine concentration
大体时间:day 31
Fasting
day 31
Plasma soluble alpha-klotho concentration
大体时间:Baseline
Fasting
Baseline
Plasma soluble alpha-klotho concentration
大体时间:day 29
Fasting
day 29
Plasma soluble alpha-klotho concentration
大体时间:day 31
Fasting
day 31
Body weight
大体时间:day 29
day 29
Body weight
大体时间:day 31
day 31
BMI
大体时间:day 29
day 29
BMI
大体时间:day 31
day 31
Waist circumference
大体时间:day 29
day 29
Waist circumference
大体时间:day 31
day 31
Hip circumference
大体时间:day 29
day 29
Hip circumference
大体时间:day 31
day 31
Percentage body fat
大体时间:Baseline
Baseline
Percentage body fat
大体时间:day 29
day 29
Percentage body fat
大体时间:day 31
day 31
Percentage lean body mass
大体时间:Baseline
Baseline
Percentage lean body mass
大体时间:day 29
day 29
Percentage lean body mass
大体时间:day 31
day 31
Heart rate variability (resting)
大体时间:Baseline
supine
Baseline
Heart rate variability (resting)
大体时间:day 29
supine
day 29
Heart rate variability (resting)
大体时间:day 31
supine
day 31
Heart rate variability (ambulatory)
大体时间:24 h recording at baseline
24 h recording at baseline
Heart rate variability (ambulatory)
大体时间:24 h recording on day 29
24 h recording on day 29
Heart rate variability (ambulatory)
大体时间:24 h recording on day 31
24 h recording on day 31
Heart rate variability (sleep-time)
大体时间:Baseline
Baseline
Heart rate variability (sleep-time)
大体时间:day 29
day 29
Heart rate variability (sleep-time)
大体时间:day 31
day 31
Heart rate variability (during mental stress)
大体时间:Baseline
Baseline
Heart rate variability (during mental stress)
大体时间:day 29
day 29
Heart rate variability (during mental stress)
大体时间:day 31
day 31
Ambulatory blood pressure 24 h
大体时间:24 h analysis at baseline
24 h analysis at baseline
Ambulatory blood pressure daytime
大体时间:Daytime analysis at baseline
Daytime analysis at baseline
Ambulatory blood pressure night-time
大体时间:Night-time analysis at baseline
Night-time analysis at baseline
Ambulatory blood pressure 24 h
大体时间:24 h analysis on day 29
24 h analysis on day 29
Ambulatory blood pressure daytime
大体时间:daytime analysis on day 29
daytime analysis on day 29
Ambulatory blood pressure night-time
大体时间:night-time analysis on day 29
night-time analysis on day 29
Ambulatory blood pressure 24 h
大体时间:24 h analysis on day 31
24 h
24 h analysis on day 31
Ambulatory blood pressure daytime
大体时间:Daytime analysis on day 31
day time
Daytime analysis on day 31
Ambulatory blood pressure night-time
大体时间:Night-time analysis on day 31
night-time
Night-time analysis on day 31
Digital volume pulse - stiffness index (SI)
大体时间:Baseline
Stiffness index
Baseline
Digital volume pulse - SI
大体时间:day 29
Stiffness index
day 29
Digital volume pulse - SI
大体时间:day 31
Stiffness index
day 31
Digital volume pulse - reflection index (RI)
大体时间:Baseline
reflection index
Baseline
Digital volume pulse - RI
大体时间:day 29
reflection index
day 29
Digital volume pulse - RI
大体时间:day 31
reflection index
day 31
Mnemonic Similarity Test
大体时间:Baseline
Baseline
Mnemonic Similarity Test
大体时间:day 29
day 29
Mnemonic Similarity Test
大体时间:day 31
day 31
Power of food scale
大体时间:Baseline
questionnaire
Baseline
Power of food scale
大体时间:day 29
questionnaire
day 29
Power of food scale
大体时间:day 31
questionnaire
day 31
COPE (not an acronym)
大体时间:Baseline
questionnaire
Baseline
COPE
大体时间:day 29
questionnaire
day 29
COPE
大体时间:day 31
questionnaire
day 31

其他结果措施

结果测量
大体时间
Adverse events
大体时间:Baseline until endpoint: day 31 (+/-1 day)
Baseline until endpoint: day 31 (+/-1 day)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2016年2月1日

初级完成 (实际的)

2016年7月1日

研究完成 (实际的)

2016年7月1日

研究注册日期

首次提交

2016年1月22日

首先提交符合 QC 标准的

2016年2月8日

首次发布 (估计)

2016年2月11日

研究记录更新

最后更新发布 (实际的)

2019年9月17日

上次提交的符合 QC 标准的更新

2019年9月13日

最后验证

2016年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅